COVID-19 vaccination guidelines for patients with multiple sclerosis
https://doi.org/10.14412/2074-2711-2021-2-157-161
Abstract
The opinion of Russian experts on the possibility of COVID-19 vaccination in patients with multiple sclerosis (MS) is presented. The authors of the consensus, based on an analysis of a large number of domestic and foreign guidelines, conclude that it is possible to use killed and inactivated vaccines. Preliminary recommendations are given for COVID-19 vaccination, taking into account the MS disease modifying therapies.
Supporting agencies: The article was published with the support and participation of All-Russian Public Organization of Disabled People with Multiple Sclerosis (PwMS RPO).
About the Authors
N. V. Khachanova
Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
1, Ostrovityanov St., Moscow 117997, Russia
N. A. Totolyan
Department of Neurology, Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
6-8, Lev Tolstoy St., Saint Petersburg 197022, Russia
Ya. V. Vlasov
Department of Neurology and Neurosurgery, Samara State Medical University, Ministry of Health of Russia;
All-Russian Public Organization of Disabled People with Multiple Sclerosis (PwMS RPO)
Russian Federation
Russian Federation
89, Chapaevskaya St., Samara 443099, Russia;
5, Naryshkinskaya Alley, Build. 2, Moscow 125167, Russia
S. A. Sivertseva
Tyumen Regional Center for Multiple Sclerosis;
All-Russian Public Organization «Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS)»
Russian Federation
Russian Federation
8/1, Yuriya Semovskikh St., Tyumen 625032, Russia
16, M. Bronnaya St., Moscow 123104, Russia
M. V. Davydovskaya
Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;
Medical Association of Physicians and Centers for Multiple Sclerosis and Other Neuroimmunological Diseasesеs (MAPMS)
Russian Federation
Russian Federation
1, Ostrovityanov St., Moscow 117997, Russia
20-22, Galernaya St., Lit. A, Saint Petersburg 190000, Russia
E. P. Evdoshenko
City Clinical Hospital Thirty-One, City Center for Multiple Sclerosis Treatment
Russian Federation
Russian Federation
1, Dynamo Pr., Saint Petersburg 197110, Russia
A. P. Prodeus
G.N. Speranskiy Children Hospital №9, Moscow Healthcare Department
Russian Federation
Russian Federation
29, Shmitovsky Proezd, Moscow 123317, Russia
M. N. Zakharova
6th neurology unit, Research Center of Neurology, Ministry of Education and Science of Russia
Russian Federation
Russian Federation
80, Volokolamskoe Shosse, Moscow 125367, Russia
N. N. Spirin
All-Russian Public Organization «Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS)»;
Department of Neurology, Medical Genetics and Neurosurgery, Yaroslavl State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
16, M. Bronnaya St., Moscow 123104, Russia
5, Revolutsionnaya St., Yaroslavl 150000, Russia 150000
A. N. Boyko
Department of Neurology, Neurosurgery, and Medical Genetics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia;
All-Russian Public Organization «Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS)»;
Institute of Clinical Neurology, Federal Center for Brain and Neurotechnology, FMBA of Russia
Russian Federation
Russian Federation
1, Ostrovityanov St., Moscow 117997, Russia
16, M. Bronnaya St., Moscow 123104, Russia
1, Ostrovityanova St., Build. 10, Moscow 117997, Russia
References
1. Gusev EI, Martynov MYu, Boyko AN, et al. Novel coronavirus infection (COVID-19) and nervous system involvement: pathogenesis, clinical manifestations, organization of neurological care. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2020;120(6):7-16. doi: 10.17116/jnevro20201200617 (In Russ.).
2. Boyko AN, Sivertseva SA, Spirin NN. Nervous system damage in COVID-19 with an emphasis on the management of patients with multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(Suppl. 1):44-7. doi: 10.14412/2074-2711-2020-1S-44-47 (In Russ.).
3. Mares J, Hartung HP. Multiple sclerosis and COVID-19. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020 Sep;164(3):217-25. doi: 10.5507/bp.2020.033. Epub 2020 Jul 17.
4. Giovannoni G, Hawkes Ch, Lechner-Scott J, et al. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord. 2020 Apr;39:102073. doi: 10.1016/j.msard.2020.102073. Epub 2020 Mar 27.
5. Louapre C, Collongues N, Stankoff B, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurol. 2020 Sep 1;77(9):1079-88. doi: 10.1001/jamaneurol.2020.2581
6. Zabalza A, Cardenas-Robledo S, Paula Tagliani P, et al. COVID-19 in multiple sclerosis patients: susceptibility, severity, risk factors and serological response. Eur J Neurol. 2020 Dec 19. doi: 10.1111/ene.14690. Online ahead of print.
7. The Canadian Network of MS Clinics (CNMSC) COVID-19 recommendations. Доступно по ссылке: https://mssociety.ca/library/document/5HYna7iVGyMLIT8moZNpw6K30PhzuWAc/original.pdf (дата обращения 15.03.2021).
8. National MS Society. COVID-19 vaccine guidance for people living with MS. Доступно по ссылке: https://www.nationalmssociety.org/coronaviruscovid-19-information/multiple-sclerosis-andcoronavirus/covid-19-vaccine-guidance#section-1 (дата обращения 15.03.2021).
9. Barts MS. SARS-CoV2 vaccine advice for people with Multiple Sclerosis. Доступно по ссылке: https://multiple-sclerosisresearch.org/2021/01/bartsms-covid-19-vaccineadvice-update/ (дата обращения 15.03.2021).
10. MS International Federation. Global COVID-19 advice for people with MS. Доступно по ссылке: https://www.msif.org/news/2020/02/10/thecoronavirus-and-ms-what-you-need-to-know/ (дата обращения 15.03.2021).
11. MS Society Medical Advisers consensus statement on MS treatment. Доступно по ссылке: https://www.mssociety.org.uk/whatwe-do/news/ms-society-medical-advisersrelease-consensus-statement-covid-19-vaccines (дата обращения 15.03.2021).
12. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata «EpiVakKorona vaktsina na osnove peptidnykh antigenov dlya profilaktiki COVID-19». LP-006504-131020 [Instructions for the medical use of the drug «EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19». LP-006504-131020]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3d79aeab-fdb0-4979-816af5732691fc34&t (accessed 15.03.2021) (In Russ.).
13. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata «Gam-Kovid-Vak-Lio kombinirovannaya vektornaya vaktsina dlya profilaktiki koronavirusnoy infektsii, vyzyvayemoy virusom SARS-CoV-2». LP-006423-250820 [Instructions for the medical use of the drug «Gam-Covid-Vac-Lyo combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus.» LP-006423-250820]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=be951906-cc2c-40ff-af19-30edb36c68ad&t (accessed 15.03.2021) (In Russ.).
14. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata «Gam-KOVID-Vak Kombinirovannaya vektornaya vaktsina dlya profilaktiki koronavirusnoy infektsii, vyzyvayemoy virusom SARS-CoV-2». LP-006395-231020 [Instructions for the medical use of the drug «Gam-COVID-Vac Combined vector vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus». LP-006395-231020]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=be951906-cc2c-40ff-af19-30edb36c68ad&t (accessed 15.03.2021) (In Russ.).
15. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata «KoviVak vaktsina koronavirusnaya inaktivirovannaya tsel'novirionnaya kontsentrrovannaya ochishchennaya». LP-006800-190221 [Instructions for medical use of the drug «KoviVak vaccine coronavirus inactivated whole virion concentrated purified». LP-006800-190221]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspxroutingGuid=71035dbe-6178-42c0-8d36-aa54e546a65b&t (accessed 15.03.2021) (In Russ.).
16. Vremennyye metodicheskiye rekomendatsii «Profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19)». Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Versiya 10 ot 08.02.2021 [Interim guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)». Ministry of Health of the Russian Federation. Version 10 dated 02/08/2021]. Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/588/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID-19_%28v.10%29-08.02.2021_%281%29.pdf (accessed 15.03.2021) (In Russ.).
17. Reyes S, Ramsay M, Ladhani S, et al. Protecting people with multiple sclerosis through vaccination. Pract Neurol. 2020 Dec;20(6):435-45. doi: 10.1136/practneurol-2020-002527. Epub 2020 Jul 6.
18. Farez M, Correale J, Armstrong MJ, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2019 Sep 24;93(13):584-94. doi: 10.1212/WNL.0000000000008157. Epub 2019 Aug 28.
19. Zrzavy T, Kollaritsch H, Rommer PS, et al. Vaccination in Multiple Sclerosis: Friend or Foe? Front Immunol. 2019 Aug 7;10:1883. doi: 10.3389/fimmu.2019.01883. eCollection 2019.
20. Lebrun C, Vukusic S. Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. Mult Scler Relat Disord. 2019 Jun;31:173-88. doi: 10.1016/j.msard.2019.04.004. Epub 2019 Apr 10.
21. Bar-Or A, Freedman MS, Kremenchutzky M, et al. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013 Aug 6;81(6):552-8. doi: 10.1212/WNL.0b013e31829e6fbf. Epub 2013 Jul 12.
22. Von Hehn C, Howard J, Liu S, et al. Immune response to vaccines is maintained in patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm. 2017 Nov 15;5(1):e409. doi: 10.1212/NXI.0000000000000409. eCollection 2018 Jan.
23. Kaufman M, Pardo G, Rossman H, et al. Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. J Neurol Sci. 2014 Jun 15;341(1-2):22-7. doi: 10.1016/j.jns.2014.03.035. Epub 2014 Mar 26.
24. Kappos L, Mehling M, Arroyo R, et al. Randomized trial of vaccination in fingolimodtreated patients with multiple sclerosis. Neurology. 2015 Mar 3;84(9):872-9. doi: 10.1212/WNL.0000000000001302. Epub 2015 Jan 30.
25. McCarthy CL, Tuohy O, Compston DAS, et al. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013 Sep 3;81(10):872-6. doi: 10.1212/WNL.0b013e3182a35215. Epub 2013 Aug 7.
26. Bar-Or A, Calkwood JC, Chognot C, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology. 2020;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380
27. Zheng C, Kar I, Kaori Chen C, et al. Multiple Sclerosis DiseaseModifying Therapy and the COVID19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020 Sep;34(9):879-96. doi: 10.1007/s40263-020-00756-y
28. Otero-Romero S, Rodriguez-Garcia J, Vilella A, et al. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement. Neurologia. Jan-Feb 2021;36(1):50-60. doi: 10.1016/j.nrl.2020.02.006. Epub 2020 Jun 17.
29. Sellner J, Rommer PS. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies. Vaccines (Basel). 2021 Jan 28;9(2):99. doi: 10.3390/vaccines9020099
30. Ciotti J, Valtcheva M, Cross A. Effects of MS disease-modifying therapies on responses to vaccinations: A review. Mult Scler Relat Disord. 2020 Oct;45:102439. doi: 10.1016/j.msard.2020.102439. Epub 2020 Aug 1.
Review
Views: 1560
Email this article 